Skip to main content
Fig. 9 | Journal of Neuroinflammation

Fig. 9

From: Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling

Fig. 9

Intraperitoneal injection of dasatinib significantly reduces LPS-stimulated Iba-1 and GFAP immunoreactivity in wild-type mice. a, c Wild-type mice were injected with dasatinib (20 mg/kg, i.p.) or vehicle (4% DMSO + 30% PEG + 5% Tween 80, i.p.) daily for 4 days, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after LPS or PBS injection, immunohistochemistry was conducted with an anti-Iba-1 antibody. b, d, e Quantification of the data in a (cortex: con, n = 8 mice; LPS, n = 9 mice; dasatinib+LPS, n = 9 mice) and c (hippocampus: con, n = 8 mice; LPS, n = 9 mice; dasatinib+LPS, n = 9 mice). f, g Wild-type mice were injected with dasatinib (20 mg/kg, i.p.) or vehicle (4% DMSO + 30% PEG + 5% Tween 80, i.p.) daily for 4 days, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after LPS or PBS injection, immunohistochemistry was conducted with an anti-GFAP antibody (cortex: con, n = 8 mice; LPS, n = 9 mice; dasatinib+LPS, n = 9 mice). h, i Quantification of the data in g (hippocampus: con, n = 8 mice; LPS, n = 9 mice; dasatinib+LPS, n = 9 mice). One-way ANOVA with Tukey’s post hoc test was used to analyze significant differences. *p < 0.05, ***p < 0.001

Back to article page